Lyt til Critical Point

AI has taken the world by storm—but not all insurance companies, or countries, are approaching the technology the same way. On this special episode of Critical Point, experts from Munich Re and Milliman who work across five continents come together for a global conversation exploring how insurers and regulators are approaching AI around the world. Plus, don’t miss Part 1 [https://www.milliman.com/en/insight/critical-point-50-artificial-intelligence-insurance-value-chain] and Part 2 [https://www.milliman.com/en/insight/critical-point-51-artificial-intelligence-machine-learning-models] of this series on AI and insurance.  You can read the episode transcript on our website [https://www.milliman.com/en/insight/critical-point-59-artificial-intelligence-global-trends].

Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs.  You can read the episode transcript on our website [https://www.milliman.com/en/insight/critical-point-episode-58-medicaid-cell-and-gene-therapies].

Healthcare costs are a hot topic as we approach open enrollment and the presidential election. In this episode of Critical Point, host Deana Bell sits down with Dave Liner and Jason Clarkson, principals at Milliman and co-authors of the Milliman Medical Index (MMI), to discuss the key drivers of 2024’s healthcare costs. They dive into the effects of government programs like Medicaid and the Inflation Reduction Act, the rising use of weight loss medications, and how these factors are shaping healthcare costs for Americans on employer-sponsored insurance. Learn how policy changes and market trends could impact your healthcare expenses and decisions in the coming year. You can read the episode transcript on our website [https://www.milliman.com/en/insight/critical-point-episode-57-healthcare-costs-election-year].

Cyber risk, climate change, new pharmaceutical therapies—as companies look for ways to manage increasing costs and unforeseen exposures, captives are a popular mechanism to insure against the unexpected. Around since the 1950s, today there are more than 7,000 captive insurers worldwide, with many headquartered in Vermont, Bermuda, and the Cayman Islands. As these insurance vehicles grow in popularity, Milliman experts answer the top 10 questions everyone’s asking about captives. You can read the episode transcript on our website [https://www.milliman.com/en/insight/critical-point-episode-56-ten-questions-about-captives].

Drugmakers are taking steps to make sure clinical trials include participants from a variety of backgrounds—and they are steadily making progress, as evidenced by new studies of multiple sclerosis and sickle cell disease. Milliman health researchers Ellyn Russo and Chris Page unpack a history of distrust in medical research, the implications of failing to attract diverse study participants, and how simple strategies like rideshare vouchers, childcare, and check-in apps can help expand a study’s reach, so more patients have access to the latest treatments and medical research moves forward. You can read the episode transcript on our website [https://www.milliman.com/en/insight/critical-point-increasing-diversity-in-clinical-trials].